- U.K. health-cost regulator NICE has given a final recommendation for the use of Cell Therapeutics' (CTIC) Pixuvri for treating advanced B-cell non-Hodgkin lymphoma.
- Cell Therapeutics now hopes that NHS commissioners "will recognize the lack of suitable treatment options that exist for patients at this stage of the disease and list Pixuvri on hospital formularies as soon as possible."
- Cell Therapeutics expects to launch Pixuvri in England and Wales in the spring.
- Shares are +8.3%. (PR)
Cell Therapeutics' Pixuvri gets final NICE recommendation
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs